Company · IMRX
Immuneering Corporation
Name as listed on its exchange; filed with the SEC as Immuneering Corp.
Nasdaq's symbol directory lists IMRX on Nasdaq as “Immuneering Corporation - Class A Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($36K); 1 company report (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Brett Matthew Hall, CHIEF SCIENTIFIC OFFICER bought $25K
- Benjamin J. Zeskind, PRESIDENT AND CEO bought $11K
Every trade (2)
- BUYBenjamin J. Zeskind, PRESIDENT AND CEO bought $11K
- BUYBrett Matthew Hall, CHIEF SCIENTIFIC OFFICER bought $25K
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition Oct 29, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.